English
Activin Blocker
Activin Blocker
Artikelnummer
BPS102121-1
Verpackungseinheit
25 µg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Application: Useful for Activin A blocking studies.
Assay Conditions: TGFβ/Activin A-Responsive Luciferase Reporter HEK293 cells were plated according to the cell line protocol (BPS Bioscience #60653). A serial dilution of Activin Blocker was prepared in Assay Medium 1B (BPS Bioscience #79617) and pre-incubated with 30 ng/ml of Activin A (Peprotech #120-14E) for one hour at 37°C with 5% CO2. The Activin Blocker and Activin A mixture were then added to the cells and incubated at 37°C with 5% CO2 overnight. The next day, luciferase activity was measured using the ONE-Step™ Luciferase Assay System (BPS Bioscience #60690). Data is shown as percent luminescence in which cells stimulated with Activin A in the absence of Activin Blocker was set at 100%.
Background: Activin A is a member of the TGFβ (transforming growth factor beta) family of proteins involved in embryonic development, hematopoiesis, cell proliferation, and cell differentiation. It is the ligand to the activin A receptor type I or type II. Upon binding, SMAD2 (mothers against decapentaplegic homolog 2) and SMAD3 are phosphorylated, complex with SMAD4 and translocate to the nucleus, regulating gene expression. Activin A can be found in macrophages, dendritic cells, and neutrophils, playing a role in cell maturation and activation. It is involved in inflammation and autoimmune disorders, such as SLE (systemic lupus erythematosus), RA (rheumatoid arthritis), and atopic dermatitis. It is also involved in bone formation. ActRIIA is a high affinity receptor, and that property can be explored for clinical applications. The use of fusion protein blockers of the activin signaling pathways, that serve as sinks for activin A and other TGFβ members, is being explored for the treatment of pulmonary hypertension, chemotherapy-induced anemia, and osteoporosis.
Description: Activin Blocker is a fusion protein composed of the extracellular domain of ActRIIA (activin A receptor type 2A variant 2), amino acids 21-135, and the Fc domain of human IgG1. This protein was affinity purified.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Host Cell Line: HEK293
Purity: ≥90%
Storage Stability: At least 12 months at -80°C.
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
Application: Useful for Activin A blocking studies.
Assay Conditions: TGFβ/Activin A-Responsive Luciferase Reporter HEK293 cells were plated according to the cell line protocol (BPS Bioscience #60653). A serial dilution of Activin Blocker was prepared in Assay Medium 1B (BPS Bioscience #79617) and pre-incubated with 30 ng/ml of Activin A (Peprotech #120-14E) for one hour at 37°C with 5% CO2. The Activin Blocker and Activin A mixture were then added to the cells and incubated at 37°C with 5% CO2 overnight. The next day, luciferase activity was measured using the ONE-Step™ Luciferase Assay System (BPS Bioscience #60690). Data is shown as percent luminescence in which cells stimulated with Activin A in the absence of Activin Blocker was set at 100%.
Background: Activin A is a member of the TGFβ (transforming growth factor beta) family of proteins involved in embryonic development, hematopoiesis, cell proliferation, and cell differentiation. It is the ligand to the activin A receptor type I or type II. Upon binding, SMAD2 (mothers against decapentaplegic homolog 2) and SMAD3 are phosphorylated, complex with SMAD4 and translocate to the nucleus, regulating gene expression. Activin A can be found in macrophages, dendritic cells, and neutrophils, playing a role in cell maturation and activation. It is involved in inflammation and autoimmune disorders, such as SLE (systemic lupus erythematosus), RA (rheumatoid arthritis), and atopic dermatitis. It is also involved in bone formation. ActRIIA is a high affinity receptor, and that property can be explored for clinical applications. The use of fusion protein blockers of the activin signaling pathways, that serve as sinks for activin A and other TGFβ members, is being explored for the treatment of pulmonary hypertension, chemotherapy-induced anemia, and osteoporosis.
Description: Activin Blocker is a fusion protein composed of the extracellular domain of ActRIIA (activin A receptor type 2A variant 2), amino acids 21-135, and the Fc domain of human IgG1. This protein was affinity purified.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Host Cell Line: HEK293
Purity: ≥90%
Storage Stability: At least 12 months at -80°C.
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
| Artikelnummer | BPS102121-1 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 102121-1 |
| Verpackungseinheit | 25 µg |
| Mengeneinheit | STK |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
